Biosimilar can be defined as a type of biological product that is highly similar to an already FDA approved drug, known as reference biological product. 

The global Remicade Biosimilar market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Remicade Biosimilar volume and value at global level, regional level and company level. From a global perspective, this report represents overall Remicade Biosimilar market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Remicade Biosimilar in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Remicade Biosimilar manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Synthon Pharmaceuticals
LG Life Sciences
Novartis (Sandoz)
Celltrion
Biocon
Hospira
Merck Serono (Merck Group)
Biogen idec Inc.
Genentech (Roche Group)

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
100mg/10ml
500mg/50ml

Segment by Application
Blood Disorders
Oncology Diseases